Emergent Product Development Seattle,llc

Aptevo Research and Development LLC

Trubion Pharmaceuticals, Inc.

Opi Vi—ip Holdco Llc

Peter Armstrong Thompson

Jeffrey A Ledbetter

Peter Robert Baum

Martha Susan Hayden-Ledbetter

William Brady

Sandy Alexander Simon

Laura Sue Grosmaire

Philip Tan

Erik Stephen Espling

Lioudmila Tchistiakova

John W Blankenship

Sateesh Kumar Natarajan

Lynda Misher

Charles G Cerveny

Alan Keith Lofquist

Cecile Morales

Christy Anne Nilsson

Robert Bader

Valerie Calabro

Maximillian T Follettie

Alwin Schuler

The composition of anti-TNFR2 antibodies are provided, as well as methods of their preparation and use. This includes methods for treating disorders associated with TNF and/or TNFR2, such as cancer.

Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor

The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.

CD37 immunotherapeutics and uses thereof

B-cell reduction using CD37-specific and CD20-specific binding molecules

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

CD86 antagonist multi-target binding proteins

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.

CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof

A binding domain polypeptide and fusion proteins thereof that recognize an IL6/IL6 receptor complex, as well as compositions and methods of use thereof.

Antagonists of IL-6

Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.

Single chain multivalent binding proteins with effector function

Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.

Materials and methods for improved immunoglycoproteins

Growing community of inventors

Bellevue, WA, United States of America

Peter Armstrong Thompson